This look ahead at hematologic malignancies in 2017 focuses on new agents being studied for the treatment of multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloproliferative neoplasms.
Robert Chen, MD
Advertisement
Articles by Robert Chen, MD
Recent advances in mantle cell lymphoma include: (1) identification of new pathways to target, (2) novel therapeutics to treat patients with relapsed/refractory disease, and (3) monitoring of minimal residual disease and adoption of a maintenance therapy approach to prevent relapses post induction or post stem cell transplantation.
Advertisement
Latest Updated Articles
- Clinical Management Updates in Mantle Cell Lymphoma
Published: April 16th 2016 | Updated:
- Outlook for 2017: Myeloma, Lymphoma, and MPNs
Published: December 24th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
HR 2541: How May Its Implementation Impact Radiation Oncology Practice?
2
Handling the Burden of Financial Toxicity While Undergoing Cancer Therapy
3
HRQOL Finds Similar Responses Between Surgery/Treatment Options in NMIBC
4
How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?
5
